125 related articles for article (PubMed ID: 35921972)
1. De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer.
He D; Chen M; Chang L; Gu J; Liu F; Gao X; Ruan Y
Cancer Lett; 2022 Nov; 549():215837. PubMed ID: 35921972
[TBL] [Abstract][Full Text] [Related]
2. Adaptive Reprogramming of
Brown KK; Spinelli JB; Asara JM; Toker A
Cancer Discov; 2017 Apr; 7(4):391-399. PubMed ID: 28255083
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
Sharma A; Janocha AJ; Hill BT; Smith MR; Erzurum SC; Almasan A
Mol Cancer Res; 2014 Sep; 12(9):1205-15. PubMed ID: 25061101
[TBL] [Abstract][Full Text] [Related]
5. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
Meng RD; Shelton CC; Li YM; Qin LX; Notterman D; Paty PB; Schwartz GK
Cancer Res; 2009 Jan; 69(2):573-82. PubMed ID: 19147571
[TBL] [Abstract][Full Text] [Related]
6. Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway.
Chen F; Zhuang M; Zhong C; Peng J; Wang X; Li J; Chen Z; Huang Y
Oncol Rep; 2015 Jan; 33(1):457-63. PubMed ID: 25333894
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus-mediated activation of pyrimidine biosynthesis drives UDP-sugar synthesis to support viral protein glycosylation.
DeVito SR; Ortiz-Riaño E; Martínez-Sobrido L; Munger J
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):18019-24. PubMed ID: 25472841
[TBL] [Abstract][Full Text] [Related]
8. HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression.
Cao XP; Cao Y; Zhao H; Yin J; Hou P
Biochem Biophys Res Commun; 2019 Aug; 516(2):457-465. PubMed ID: 31229266
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
10. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer.
Qian X; Xu W; Xu J; Shi Q; Li J; Weng Y; Jiang Z; Feng L; Wang X; Zhou J; Jin H
Oncotarget; 2017 Jul; 8(29):47691-47708. PubMed ID: 28548950
[TBL] [Abstract][Full Text] [Related]
11. Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.
Dong Q; Zhou C; Ren H; Zhang Z; Cheng F; Xiong Z; Chen C; Yang J; Gao J; Zhang Y; Xu L; Fang J; Cao Y; Wei H; Wu Z
Cell Commun Signal; 2020 Oct; 18(1):167. PubMed ID: 33097055
[TBL] [Abstract][Full Text] [Related]
12. Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin.
Zhang X; Chen J; Ai Z; Zhang Z; Lin L; Wei H
Life Sci; 2018 Dec; 215():1-10. PubMed ID: 30473023
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
14. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Karle JM; Cowan KH; Chisena CA; Cysyk RL
Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities.
Robinson AD; Eich ML; Varambally S
Cancer Lett; 2020 Feb; 470():134-140. PubMed ID: 31733288
[TBL] [Abstract][Full Text] [Related]
16. Metabolic enzyme PDK3 forms a positive feedback loop with transcription factor HSF1 to drive chemoresistance.
Xu J; Shi Q; Xu W; Zhou Q; Shi R; Ma Y; Chen D; Zhu L; Feng L; Cheng AS; Morrison H; Wang X; Jin H
Theranostics; 2019; 9(10):2999-3013. PubMed ID: 31244938
[No Abstract] [Full Text] [Related]
17. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
18. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals.
Li T; Ma G; Cai H; Price DL; Wong PC
J Neurosci; 2003 Apr; 23(8):3272-7. PubMed ID: 12716934
[TBL] [Abstract][Full Text] [Related]
19. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells.
Wang X; Yang K; Wu Q; Kim LJY; Morton AR; Gimple RC; Prager BC; Shi Y; Zhou W; Bhargava S; Zhu Z; Jiang L; Tao W; Qiu Z; Zhao L; Zhang G; Li X; Agnihotri S; Mischel PS; Mack SC; Bao S; Rich JN
Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391321
[TBL] [Abstract][Full Text] [Related]
20. Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators.
Rivkin A; Ahearn SP; Chichetti SM; Kim YR; Li C; Rosenau A; Kattar SD; Jung J; Shah S; Hughes BL; Crispino JL; Middleton RE; Szewczak AA; Munoz B; Shearman MS
Bioorg Med Chem Lett; 2010 Feb; 20(3):1269-71. PubMed ID: 20022243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
